Zai Lab Ltd ZLAB
4 trading plans running, 38 Form 144 notices for $13.6M
10-Q, 10-K and Form 144What ZLAB's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Nov 22, 2024 to Sep 16, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| F. Ty Edmondson Chief Legal Officer and Corporate Secretary |
Adopted 10b5-1 plan | Sep 16, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn September 16, 2026, F. Ty Edmondson, the Company’s Chief Legal Officer and Corporate Secretary, adopted a new written Rule 10b5-1 trading arrangement for (1) the sale of ADSs up to $300,000 and (2) the sale of up to 12,500 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 16, 2027. | |||||
| William Lis director |
Adopted 10b5-1 plan | Aug 11, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn August 11, 2026, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 23,048 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 16, 2027. | |||||
| Richard Gaynor directors |
Adopted 10b5-1 plan | Dec 16, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 16, 2025, Richard Gaynor, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the purchase of ADSs with a price of up to $99,000. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 31, 2026. | |||||
| Rafael Amado President and Head of Global Research and Development |
Adopted 10b5-1 plan | Nov 14, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn November 14, 2025, Rafael Amado, the Company’s President and Head of Global Research and Development, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 20,000 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 17, 2026. | |||||
| Dr. Samantha (Ying) Du Founder, Chief Executive officer, and Chairperson of the Board |
Adopted 10b5-1 plan | Nov 10, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn November 10, 2025, Dr. Samantha (Ying) Du, the Company’s Founder, Chief Executive officer, and Chairperson of the Board, adopted a new written Rule 10b5-1 trading arrangement, for (1) the acquisition and sale of up to 400,000 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2026 and (2) for the acquisition of up to 261,092 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2026. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 9, 2026. | |||||
| F. Ty Edmondson Chief Legal Officer and Corporate Secretary |
Adopted 10b5-1 plan | Sep 12, 2025 | 10-Q Nov 6, 2025 | ||
What the company wroteOn September 12, 2025, F. Ty Edmondson, the Company’s Chief Legal Officer and Corporate Secretary, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 42,065 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 13, 2026. | |||||
| William Lis director |
Adopted 10b5-1 plan | Sep 10, 2025 | 10-Q Nov 6, 2025 | ||
What the company wroteOn September 10, 2025, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 15,547 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 14, 2026. | |||||
| William Lis directors |
Adopted 10b5-1 plan | Mar 4, 2025 | 10-Q May 8, 2025 | ||
What the company wroteOn March 4, 2025, William Lis, one of the Company’s directors, amended his written Rule 10b5-1 trading arrangement adopted on November 20, 2024. Mr. Lis increased the number of shares to be sold pursuant to the plan by 2,125 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than June 1, 2026. | |||||
| Yajing Chen Chief Financial Officer |
Adopted 10b5-1 plan | Mar 3, 2025 | 10-Q May 8, 2025 | ||
What the company wroteOn March 3, 2025, Yajing Chen, the Company’s Chief Financial Officer, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 15,494 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than March 4, 2026. | |||||
| F. Ty Edmondson Chief Legal Officer |
Adopted 10b5-1 plan | Nov 22, 2024 | 10-K Feb 27, 2025 | ||
| Rafael Amado President and Head of Global Research and Development |
Adopted 10b5-1 plan | Nov 22, 2024 | 10-K Feb 27, 2025 | ||
| Dr. Samantha (Ying) Du Founder, Chief Executive officer, and Chairperson of the Board |
Adopted 10b5-1 plan | Nov 20, 2024 | 10-K Feb 27, 2025 | ||
| William Lis director |
Adopted 10b5-1 plan | Nov 20, 2024 | 10-K Feb 27, 2025 | ||
| Richard Gaynor director |
Adopted 10b5-1 plan | Jun 6, 2024 | 10-Q Aug 6, 2024 | ||
What the company wroteOn June 6, 2024, Richard Gaynor, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the disposition of up to 5,000 of the Company’s ADSs, each representing ten of the Company’s ordinary shares, to cover tax obligations in connection with the vesting of a previously granted restricted stock award. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than July 7, 2025. | |||||
| Joshua Smiley President and Chief Operating Officer |
Ended plan | May 13, 2024 | 10-Q Nov 7, 2023 | ||
What the company wroteOn August 12, 2023, Joshua Smiley, the Company’s President and Chief Operating Officer, adopted a new written Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K), for the purchase of up to 15,000 of the Company’s ADSs, each representing ten of the Company’s ordinary shares. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than May 13, 2024. | |||||
| William Lis director |
Adopted 10b5-1 plan | Feb 23, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn February 23 , 2024, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the disposition of up to 10,397 of the Company’s ADSs, each representing ten of the Company’s ordinary shares, to cover tax obligations in connection with the vesting of a previously granted restricted stock award . This Rule 10b5-1 trading arrangement is scheduled to terminate no later than July 31, 2024. | |||||
| Rafael Amado President and Head of Global Oncology Research and Development |
Adopted 10b5-1 plan | Dec 15, 2023 | 10-K Feb 27, 2024 | ||
What the company wroteOn December 15, 2023, Rafael Amado, the Company’s President and Head of Global Oncology Research and Development, adopted a new written Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K), for the sale of up to 94,500 of the Company’s ADSs, each representing ten of the Company’s ordinary shares. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 16, 2024. | |||||
Show the other 9 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 20, 2026 | Smiley Joshua L Former Officer |
98,653 | $2.6M |
| Aug 19, 2026 | Chen Yajing Officer |
260 | $7K |
| Aug 12, 2026 | Lis William Director |
8,506 | $213K |
| Aug 11, 2026 | Chen Yajing Officer |
619 | $15K |
| Jun 30, 2026 | Du Ying Officer, Director |
7,026 | $130K |
| Jun 26, 2026 | Chen Yajing Officer |
2,264 | $40K |
| Jun 26, 2026 | Edmondson Frazor Titus III Officer |
4,103 | $72K |
| Jun 26, 2026 | Du Ying Officer, Director |
24,543 | $429K |
| Jun 22, 2026 | Lis William Director |
7,040 | $127K |
| May 18, 2026 | Du Ying Officer, Director |
50,000 | $976K |
| May 15, 2026 | Du Ying Officer, Director |
50,000 | $1.0M |
| May 14, 2026 | Du Ying Officer, Director |
50,000 | $1.0M |
| May 14, 2026 | Edmondson Frazor Titus III Officer |
3,517 | $71K |
| May 13, 2026 | Du Ying Officer, Director |
50,000 | $960K |
| Apr 6, 2026 | Smiley Joshua L Officer |
3,017 | $62K |
| Apr 6, 2026 | Du Ying Officer, Director |
2,653 | $54K |
| Apr 6, 2026 | Edmondson Frazor Titus III Officer |
1,224 | $25K |
| Apr 6, 2026 | Amado Rafael Officer |
2,739 | $56K |
| Apr 6, 2026 | Chen Yajing Officer |
853 | $17K |
| Apr 2, 2026 | Amado Rafael Officer |
9,910 | $202K |
| Apr 2, 2026 | Du Ying Officer, Director |
5,576 | $114K |
| Apr 2, 2026 | Smiley Joshua L Officer |
9,614 | $196K |
| Apr 2, 2026 | Edmondson Frazor Titus III Officer |
4,194 | $86K |
| Apr 2, 2026 | Chen Yajing Officer |
5,199 | $106K |
| Mar 13, 2026 | Edmondson Frazor Titus III Officer |
1,281 | $24K |
| Mar 13, 2026 | Smiley Joshua L Officer |
1,966 | $37K |
| Mar 13, 2026 | Amado Rafael Officer |
2,957 | $55K |
| Mar 13, 2026 | Chen Yajing Officer |
1,703 | $32K |
| Mar 11, 2026 | Du Ying Officer, Director |
1,067 | $20K |
| Mar 9, 2026 | Du Ying Officer, Director |
50,000 | $960K |
| Mar 6, 2026 | Du Ying Officer, Director |
50,000 | $959K |
| Mar 5, 2026 | Edmondson Frazor Titus III Officer |
15,569 | $297K |
| Mar 5, 2026 | Du Ying Officer, Director |
50,000 | $953K |
| Mar 4, 2026 | Du Ying Officer, Director |
50,000 | $914K |
| Mar 3, 2026 | Amado Rafael Officer |
10,000 | $174K |
| Dec 31, 2025 | Amado Rafael Officer |
10,787 | $188K |
| Dec 16, 2025 | Edmondson Frazor Titus III Officer |
8,651 | $148K |
| Nov 21, 2025 | Edmondson Frazor Titus III Officer |
14,328 | $283K |
Show the other 30 notices
From the Form 144 XML filed with the SEC, since Nov 21, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZLAB/export.csv") into a cell.